Clinical Research & Reference Standard Compendium
CJC-1295 (with DAC) Spray - Scientific Literature
I. Abstract & Overview
CJC-1295 with DAC is a 29-residue analog of growth hormone-releasing hormone carrying four engineered substitutions plus a Drug Affinity Complex, a maleimide group designed to form a covalent bond with a free cysteine thiol on circulating albumin. Jetté and colleagues reported in 2005 that human growth hormone-releasing factor albumin bioconjugates activate the receptor on the anterior pituitary, establishing that conjugation does not abolish receptor engagement. Teichman and colleagues subsequently reported prolonged growth hormone and insulin-like growth factor 1 secretion in 2006. The covalent conjugation strategy distinguishes it sharply from the reversible fatty-acid acylation used on GLP-1 analogs such as Semaglutide, and from the non-DAC version of the same peptide backbone. Research Use Only (RUO).
II. Chemical Specifications
| Molecular Formula | C165H269N47O46 |
|---|---|
| Molar Mass | 3647.2 g/mol (PubChem CID 91971820) |
| CAS Registry Number | 446262-90-4 |
| Amino Acid Sequence | 29-residue GHRH analog with four engineered substitutions plus a maleimidoproprionyl Drug Affinity Complex at the C-terminal lysine — verify the exact conjugation site with manufacturer COA |
III. Mechanism & Cellular Signaling Pathways
Receptor engagement is conventional for a GHRH analog: binding to the GHRH receptor on pituitary somatotroph cells couples through Gs to adenylyl cyclase, raising cAMP and activating protein kinase A, which phosphorylates CREB and drives Pit-1-dependent transcription of the growth hormone gene. The distinguishing mechanism sits outside the receptor entirely. The Drug Affinity Complex terminates in a maleimide, a group that reacts specifically and covalently with free thiols, and serum albumin presents exactly one accessible cysteine thiol. The resulting conjugate is a permanent chemical bond rather than an association. Research shows this differs fundamentally from the fatty-acid acylation strategy used on Semaglutide and Tirzepatide, where albumin binding is reversible and the peptide continuously exchanges between bound and free states. The four backbone substitutions independently block enzymatic degradation.
IV. Primary Research Directions
- **Covalent Albumin Conjugation:** Research shows the maleimide group forms a permanent bond with the single free cysteine thiol on serum albumin, verifiable by incubating with purified albumin and following adduct formation.
- **Receptor Engagement After Conjugation:** Jetté and colleagues (2005) demonstrated albumin bioconjugates still activate the pituitary receptor, the control that validates the whole design.
- **Prolonged Secretion Profile:** Teichman and colleagues (2006) reported sustained growth hormone and IGF-1 elevation, giving a time-course readout the non-DAC version cannot provide.
- **Covalent Versus Reversible Comparison:** Laboratory investigations pair it against fatty-acid-acylated peptides such as Semaglutide to contrast permanent conjugation with reversible albumin association.
- **DAC Versus Non-DAC Controls:** Studies indicate the two versions share receptor pharmacology but differ entirely in duration, making the pair a clean way to isolate conjugation effects from receptor effects.
V. Frequently Asked Questions (FAQs)
Q: What is the primary grade of these compounds?
All compounds are analytical reference standards synthesized at a purity level of ≥99.0%, verified by HPLC and Mass Spectrometry.
Q: Are these peptides intended for human consumption?
No. Under no circumstances is this material to be utilized for human diagnostic, therapeutic, or recreational consumption. Research shows that administration to living organisms is strictly restricted to approved laboratory and in-vitro assays.
Q: How does research show these peptides should be stored?
Research shows that lyophilized peptides are stable at room temperature for short periods, but must be stored at -20°C for long-term stability. Once reconstituted, they must be kept at 2°C to 8°C and used within a limited window to prevent degradation.
Q: What is reconstitution and what solvent should be used?
Reconstitution is the process of dissolving the lyophilized powder. Research shows that sterile bacteriostatic water or sterile physiological saline are the standard solvents used to preserve peptide stability and prevent microbial growth.
Q: What does the HPLC chromatogram represent?
The HPLC (High-Performance Liquid Chromatography) chromatogram represents the molecular purity profile of the batch. Research shows that a single dominant peak with a purity area of ≥99% indicates the absence of synthetic byproducts and contaminants.
Q: Can these research compounds be combined in a single study?
Yes. Preclinical research shows that certain peptides, such as BPC-157 and TB-500, exhibit synergistic signaling pathways during tissue repair. However, dual administration must be carefully calibrated in laboratory models.
Q: Why is molar mass and molecular formula variance important?
Molecular formula and molar mass are fingerprinted identifiers. Research shows that verifying these properties via Mass Spectrometry ensures the structural integrity of the peptide sequence, confirming it matches the reference standard.
Q: What documentation is provided for regulatory compliance?
Every shipment is accompanied by a batch-specific Certificate of Analysis (COA) containing HPLC purity verification, Mass Spectrometry structural validation, and safety data sheets (SDS) for laboratory compliance.
VI. Academic Citations
- Teichman, S. L., Neale, A., Lawrence, B., et al. (2006). 'Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.' Journal of Clinical Endocrinology and Metabolism, 91(3), 799-805. DOI: 10.1210/jc.2005-1536 | PMID: 16352683
- Jetté, L., Léger, R., Thibaudeau, K., et al. (2005). 'Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats.' Endocrinology, 146(7), 3052-3058. DOI: 10.1210/en.2004-1286 | PMID: 15817669
- Halmos, G., Szabo, Z., Juhasz, E., et al. (2023). 'Signaling mechanism of growth hormone-releasing hormone receptor.' Vitamins and Hormones, 123, 1-26. DOI: 10.1016/bs.vh.2023.06.004 | PMID: 37717982
CJC-1295 (with DAC) Spray
Abstract & Overview
CJC-1295 with DAC is a 29-residue analog of growth hormone-releasing hormone carrying four engineered substitutions plus a Drug Affinity Complex, a maleimide group designed to form a covalent bond with a free cysteine thiol on circulating albumin. Jetté and colleagues reported in 2005 that human growth hormone-releasing factor albumin bioconjugates activate the receptor on the anterior pituitary, establishing that conjugation does not abolish receptor engagement. Teichman and colleagues subsequently reported prolonged growth hormone and insulin-like growth factor 1 secretion in 2006. The covalent conjugation strategy distinguishes it sharply from the reversible fatty-acid acylation used on GLP-1 analogs such as Semaglutide, and from the non-DAC version of the same peptide backbone. Research Use Only (RUO).
Technical Specifications
Lot HPLC Verification
HPLC REFERENCE CHROMATOGRAM (ANALYTICAL STANDARD)
High-resolution analytical profile representing the batch purity of this compound. Peak area integration confirms purity verification of ≥99.0%.
Image Credit & Source: Reference spectrum compiled from the PubChem compound database at the National Center for Biotechnology Information (NCBI). Calibrated analytical simulation for product purity control assays.
HPLC Method Conditions
| Peak | Retention Time | Area (mAU*s) | Area % |
|---|---|---|---|
| 1 (Impurity) | 2.10 | 12.5 | 0.35% |
| 2 (CJC-1295 (with DAC) Spray) | 9.80 | 3562.4 | 99.65% |
How to Read This Report: What Does This Graph Prove?
The tall spike at 9.80 minutes represents the active compound (CJC-1295 (with DAC) Spray). A single clean, tall peak confirms high concentration.
The total area under the main peak accounts for 99.65% of the material. This mathematically verifies the high-purity rating of the batch.
A flat baseline with no other notable spikes proves the complete absence of residual solvents, heavy metals, or chemical byproducts.
Mechanism & Signaling
Receptor engagement is conventional for a GHRH analog: binding to the GHRH receptor on pituitary somatotroph cells couples through Gs to adenylyl cyclase, raising cAMP and activating protein kinase A, which phosphorylates CREB and drives Pit-1-dependent transcription of the growth hormone gene. The distinguishing mechanism sits outside the receptor entirely. The Drug Affinity Complex terminates in a maleimide, a group that reacts specifically and covalently with free thiols, and serum albumin presents exactly one accessible cysteine thiol. The resulting conjugate is a permanent chemical bond rather than an association. Research shows this differs fundamentally from the fatty-acid acylation strategy used on Semaglutide and Tirzepatide, where albumin binding is reversible and the peptide continuously exchanges between bound and free states. The four backbone substitutions independently block enzymatic degradation.
Primary Research Directions
**Covalent Albumin Conjugation:** Research shows the maleimide group forms a permanent bond with the single free cysteine thiol on serum albumin, verifiable by incubating with purified albumin and following adduct formation.
**Receptor Engagement After Conjugation:** Jetté and colleagues (2005) demonstrated albumin bioconjugates still activate the pituitary receptor, the control that validates the whole design.
**Prolonged Secretion Profile:** Teichman and colleagues (2006) reported sustained growth hormone and IGF-1 elevation, giving a time-course readout the non-DAC version cannot provide.
**Covalent Versus Reversible Comparison:** Laboratory investigations pair it against fatty-acid-acylated peptides such as Semaglutide to contrast permanent conjugation with reversible albumin association.
**DAC Versus Non-DAC Controls:** Studies indicate the two versions share receptor pharmacology but differ entirely in duration, making the pair a clean way to isolate conjugation effects from receptor effects.
Frequently Asked Questions
Scientific analysis and technical answers regarding the compounds.
What is the primary grade of these compounds?
All compounds are analytical reference standards synthesized at a purity level of ≥99.0%, verified by HPLC and Mass Spectrometry.
02Are these peptides intended for human consumption?
+
Are these peptides intended for human consumption?
No. Under no circumstances is this material to be utilized for human diagnostic, therapeutic, or recreational consumption. Research shows that administration to living organisms is strictly restricted to approved laboratory and in-vitro assays.
03How does research show these peptides should be stored?
+
How does research show these peptides should be stored?
Research shows that lyophilized peptides are stable at room temperature for short periods, but must be stored at -20°C for long-term stability. Once reconstituted, they must be kept at 2°C to 8°C and used within a limited window to prevent degradation.
04What is reconstitution and what solvent should be used?
+
What is reconstitution and what solvent should be used?
Reconstitution is the process of dissolving the lyophilized powder. Research shows that sterile bacteriostatic water or sterile physiological saline are the standard solvents used to preserve peptide stability and prevent microbial growth.
05What does the HPLC chromatogram represent?
+
What does the HPLC chromatogram represent?
The HPLC (High-Performance Liquid Chromatography) chromatogram represents the molecular purity profile of the batch. Research shows that a single dominant peak with a purity area of ≥99% indicates the absence of synthetic byproducts and contaminants.
06Can these research compounds be combined in a single study?
+
Can these research compounds be combined in a single study?
Yes. Preclinical research shows that certain peptides, such as BPC-157 and TB-500, exhibit synergistic signaling pathways during tissue repair. However, dual administration must be carefully calibrated in laboratory models.
07Why is molar mass and molecular formula variance important?
+
Why is molar mass and molecular formula variance important?
Molecular formula and molar mass are fingerprinted identifiers. Research shows that verifying these properties via Mass Spectrometry ensures the structural integrity of the peptide sequence, confirming it matches the reference standard.
08What documentation is provided for regulatory compliance?
+
What documentation is provided for regulatory compliance?
Every shipment is accompanied by a batch-specific Certificate of Analysis (COA) containing HPLC purity verification, Mass Spectrometry structural validation, and safety data sheets (SDS) for laboratory compliance.
Scientific Citations
Teichman, S. L., Neale, A., Lawrence, B., et al. (2006). 'Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.' Journal of Clinical Endocrinology and Metabolism, 91(3), 799-805. DOI: 10.1210/jc.2005-1536 | PMID: 16352683
Jetté, L., Léger, R., Thibaudeau, K., et al. (2005). 'Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats.' Endocrinology, 146(7), 3052-3058. DOI: 10.1210/en.2004-1286 | PMID: 15817669
Halmos, G., Szabo, Z., Juhasz, E., et al. (2023). 'Signaling mechanism of growth hormone-releasing hormone receptor.' Vitamins and Hormones, 123, 1-26. DOI: 10.1016/bs.vh.2023.06.004 | PMID: 37717982
Academic Disclaimer
All chemical compounds supplied by 99 Purity Wholesale are strictly engineered and distributed for laboratory research, chemical analysis, and in-vitro testing. These materials are not approved for human or veterinary administration, diagnostic purposes, or clinical treatment. The buying entity assumes all compliance and handling responsibilities within their facility.
